Oracle Corporation
ORCLOracle Corporation's earnings have outrun its stock. EPS grew +34.3% in a year against a −53.6% price move.
The sharpest disagreement: annual EPS moved +34.3% against a −53.6% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (15 weeks in) while the P/E sits at the 1st percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +59.7% year on year, and 179% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Oracle Corporation trades at $143, in a downtrend and 15 weeks into that stage. That is −14.2% against its own 200-day average. It sits at 16% of a 52-week range of $115 to $293. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (13 weeks and counting).
Today the stock is in a downtrend — week 15 of stage 4. At $143 it trades −14.2% versus its 200-day average and sits at 16% of its 52-week range ($115–$293).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +250% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (13 weeks and counting; last ahead the week of 2026-06-18) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Oracle Corporation trades at 22.0× P/E, about the cheapest it has ever traded. Its long-run median P/E is 33.9×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 22.0× is about the cheapest it has ever traded, against a long-run median of 33.9× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +34.3% against a −53.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +7.9%/yr price move, ~+23.9%/yr came from earnings growth and ~−16.0 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Oracle Corporation reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROCE at 12.4% is below the 15% bar this page requires to call it Consistent. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +17.4% | +10.5% | — | — |
| Profit | +36.5% | +25.9% | — | — |
| EPS | +34.3% | +23.8% | — | — |
| Stock price | −53.6% | +7.9% | +10.6% | +13.9% |
4-Factor Sector Score
51.5/100 — rank 12 of 28 in Software - Infrastructure · 85% evidence confidence
Oracle Corporation scores 51.5 out of 100 against the 28 companies it is compared with in Software - Infrastructure, ranking 12. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 19.9 + 15.5 + 15.6 + 0.5 = 51.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Oracle Corporation reported $19.3 B of revenue in the Aug 26 quarter, +29.5% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 12.2% a year. The last full year, FY26, came in at $67.4 B. The last four reported quarters add to $71.8 B.
FY26 revenue came in at $67.4 B (+17.4% on the year), capping 4 years at 12.2% compound. The latest quarter (Aug 26) printed $19.3 B, +29.5% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +21.5% growth against the decade's 12.2% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +21.6% over the last 4 quarters against +15.5%/yr over the last 8 — accelerating; TTM profit +50.4% vs +30.7%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Oracle Corporation's operating margin is 35.3% in the Aug 26 quarter, +4.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 27.4% to 37.3%. The current quarter sits inside that band.
The latest quarter's operating margin is 35.3%, +4.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 27.4%–37.3%.
Why the margin moved: operating margin went +4.0 pp year on year while gross margin went −7.2 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Oracle Corporation earned $4.7 B of net profit in the Aug 26 quarter, +59.7% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was $17.0 B. The 4-year compound rate is 26.1%. That is 24.2% of the quarter's revenue. The same quarter a year earlier earned $2.9 B.
Aug 26 profit was $4.7 B, +59.7% year on year — the 4th consecutive quarter of growth. On the full year, FY26 printed $17.0 B (+36.5%), and the 4-year compound rate is 26.1%.
Why profit moved: revenue contributed +29.5% and the margin +4.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +50.8% vs revenue +21.5%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 179% of Oracle Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was $32.0 B of operating cash against $17.0 B of profit. After $55.7 B of capital spending, $−23.7 B was left as free cash.
FY26: operating cash of $32.0 B against reported profit of $17.0 B, leaving free cash of $−23.7 B after $55.7 B of capital spending. Across the last 3 fiscal years the conversion rate is 179% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Oracle Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $84.0 B over the last 3 years. Averaged over those years that is 41.6% of FY26 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $84.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Oracle Corporation earns a ROE of 39% in FY26. That is up from a trough of −117% in FY22. Return on invested capital clears the cost of that capital by +0.7 percentage points, so growth here adds value rather than only size. The wiring behind it is 25.2% net margin on 0.26× asset turns.
FY26 ROE is 39%, recovered from a FY22 trough of −117% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 25.2% net margin × 0.26× asset turns × 6.08× balance-sheet leverage ≈ 39.8% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 11.3% − 10.6% = a +0.7 pp spread. The 10.6% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Oracle Corporation paid $2.00 per share over the last four reported quarters. The most recent declaration was $0.50 for Aug 26. Against the current price of $143 that is a trailing yield of 1.40%, measured on dividends already paid rather than on a forecast.
Oracle Corporation paid $2.00 per share across the last four reported quarters, most recently $0.50 for Aug 26. Against the current price of $143 the trailing twelve months work out to 1.40% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Oracle Corporation carries total debt of $156 B against shareholder equity of $67.2 B as of Aug 26, a debt-to-equity of 2.32. On the annual view that ratio went from −13.15 in FY22 to 3.89 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Aug 26: total debt of $156 B against shareholder equity of $67.2 B — a debt-to-equity of 2.32. On the annual view, debt-to-equity went from −13.15 (FY22) to 3.89 (FY26). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
2.4% of Oracle Corporation's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 1.8 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 2.4% of the float is sold short, and at typical trading volumes it would take about 1.8 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Oracle Corporation: the Z-score reads 1.93. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 1.93 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 1.93.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Palantir Technologies Inc.PLTR | 69.6/100Favorable setup71% evidence | BREAKING OUT | 30.0/35 Revenue 78.8% · PAT 100% · OPM change 20.3 pp 83% evidence | 19.9/25 ROCE 26% · OPM 47.1% 76% evidence | 9.2/20 P/E 92.7× · PEG — 15% evidence | 10.5/20 RS sector -12% · RS bench 4.1% · 1Y -4.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 30 + 19.9 + 9.2 + 10.5 = 69.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Corpay, Inc.CPAY | 64.2/100Mixed-positive evidence81% evidence | LEADER | 22.6/35 Revenue 20.4% · PAT 8% · OPM change 3.4 pp 83% evidence | 20.5/25 ROCE 21.2% · OPM 46.9% 76% evidence | 11.3/20 P/E 19.2× · PEG 1.65 65% evidence | 9.8/20 RS sector -3.6% · RS bench 14.1% · 1Y 33.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 20.5 + 11.3 + 9.8 = 64.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Microsoft CorporationMSFT | 63.8/100Mixed-positive evidence81% evidence | BREAKING OUT | 18.4/35 Revenue 17.8% · PAT 31.3% · OPM change 0.2 pp 83% evidence | 21.2/25 ROCE 26.3% · OPM 45.1% 76% evidence | 15.3/20 P/E 20.7× · PEG 0.65 65% evidence | 8.9/20 RS sector -13.1% · RS bench 2.7% · 1Y -5.3%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 21.2 + 15.3 + 8.9 = 63.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4NetApp, Inc.NTAP | 60.0/100Mixed-positive evidence81% evidence | LEADER | 19.1/35 Revenue 5.4% · PAT 7.6% · OPM change 7.2 pp 83% evidence | 15.3/25 ROCE 8.3% · OPM 27.3% 76% evidence | 12.5/20 P/E 17.1× · PEG 1.43 65% evidence | 13.1/20 RS sector 18.1% · RS bench 38% · 1Y 53%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 15.3 + 12.5 + 13.1 = 60 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Okta, Inc.OKTA | 59.2/100Mixed-positive evidence71% evidence | LEADER | 20.4/35 Revenue 11.8% · PAT 90% · OPM change 1.6 pp 83% evidence | 9.4/25 ROCE 2.4% · OPM 7.3% 76% evidence | 9.5/20 P/E 52.7× · PEG — 15% evidence | 19.9/20 RS sector 48.3% · RS bench 72.9% · 1Y 101.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 9.4 + 9.5 + 19.9 = 59.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Fortinet, Inc.FTNT | 57.8/100Mixed-positive evidence81% evidence | LEADER | 22.8/35 Revenue 18.8% · PAT 9.3% · OPM change 5.6 pp 83% evidence | 16.9/25 ROCE 11.6% · OPM 33.7% 76% evidence | 4.4/20 P/E 54.1× · PEG 4.11 65% evidence | 13.7/20 RS sector 28.9% · RS bench 50.5% · 1Y 104%10 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 16.9 + 4.4 + 13.7 = 57.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 7Rubrik, Inc.RBRK | 57.0/100Mixed-positive evidence61% evidence | LEADER | 24.9/35 Revenue 45.9% · PAT — · OPM change 19.8 pp 62% evidence | 3.8/25 ROCE -5.3% · OPM -13.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 18.3/20 RS sector 18.5% · RS bench 38.6% · 1Y 30.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 3.8 + 10 + 18.3 = 57 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Nutanix, Inc.NTNX | 56.1/100Mixed-positive evidence71% evidence | BREAKING OUT | 19.6/35 Revenue -1.9% · PAT 100% · OPM change 5.2 pp 83% evidence | 11.0/25 ROCE 3.7% · OPM 19.3% 76% evidence | 9.6/20 P/E 43× · PEG — 15% evidence | 15.9/20 RS sector 3.9% · RS bench 21.6% · 1Y -10.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 11 + 9.6 + 15.9 = 56.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9CrowdStrike Holdings, Inc.CRWD | 54.9/100Mixed-positive evidence67% evidence | LEADER | 23.1/35 Revenue 24.3% · PAT — · OPM change 3.4 pp 71% evidence | 5.3/25 ROCE -1.6% · OPM -2.3% 76% evidence | 8.5/20 P/E 3324.4× · PEG — 15% evidence | 18.0/20 RS sector 36.9% · RS bench 59.6% · 1Y 92.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 23.1 + 5.3 + 8.5 + 18 = 54.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10GoDaddy Inc.GDDY | 53.6/100Thin evidence · provisional56% evidence | BREAKING OUT | 20.7/35 Revenue — · PAT — · OPM change 3.8 pp 39% evidence | 14.7/25 ROCE 6.8% · OPM 24.5% 76% evidence | 11.4/20 P/E 12.6× · PEG — 15% evidence | 6.8/20 RS sector -23.4% · RS bench -9.4% · 1Y -31.5%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 14.7 + 11.4 + 6.8 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Gen Digital Inc.GEN | 52.7/100Mixed-positive evidence71% evidence | BREAKING OUT | 17.7/35 Revenue 27.1% · PAT 51.3% · OPM change -6.4 pp 53% evidence | 15.3/25 ROCE 6.3% · OPM 62.6% 76% evidence | 8.0/20 P/E 12× · PEG 2.71 65% evidence | 11.7/20 RS sector -3.6% · RS bench 13.5% · 1Y 5.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 15.3 + 8 + 11.7 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Oracle Corporationthis pageORCL | 51.5/100Mixed-positive evidence85% evidence | BASING | 19.9/35 Revenue 21.6% · PAT 50.6% · OPM change 3.9 pp 95% evidence | 15.5/25 ROCE 9.6% · OPM 35.3% 76% evidence | 15.6/20 P/E 22.9× · PEG 0.48 65% evidence | 0.5/20 RS sector -38.5% · RS bench -27.3% · 1Y -53.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.9 + 15.5 + 15.6 + 0.5 = 51.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13F5, Inc.FFIV | 50.3/100Mixed-positive evidence81% evidence | TURNING | 14.5/35 Revenue 9.4% · PAT 8.8% · OPM change -0.6 pp 83% evidence | 18.3/25 ROCE 16.3% · OPM 24.6% 76% evidence | 5.7/20 P/E 32.3× · PEG 3.03 65% evidence | 11.8/20 RS sector 4.8% · RS bench 23.4% · 1Y 28.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 18.3 + 5.7 + 11.8 = 50.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 14Toast, Inc.TOST | 50.1/100Thin evidence · provisional56% evidence | BREAKING OUT | 22.5/35 Revenue 23.4% · PAT 100% · OPM change 3.5 pp 53% evidence | 10.7/25 ROCE 5.9% · OPM 6.7% 57% evidence | 9.8/20 P/E 40.8× · PEG — 15% evidence | 7.1/20 RS sector -21.1% · RS bench -6.7% · 1Y -24.3%8 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 10.7 + 9.8 + 7.1 = 50.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Twilio Inc.TWLO | 49.9/100Mixed-negative evidence64% evidence | TURNING | 18.1/35 Revenue 17.8% · PAT — · OPM change 2.6 pp 62% evidence | 7.3/25 ROCE 0.9% · OPM 5.6% 76% evidence | 10.4/20 P/E 28.7× · PEG — 15% evidence | 14.1/20 RS sector 21.6% · RS bench 42.4% · 1Y 124.3%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 7.3 + 10.4 + 14.1 = 49.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Samsara Inc.IOT | 49.8/100Mixed-negative evidence64% evidence | BREAKING OUT | 24.4/35 Revenue 29.6% · PAT — · OPM change 10.6 pp 62% evidence | 6.0/25 ROCE -0.7% · OPM 1.5% 76% evidence | 8.6/20 P/E 308.9× · PEG — 15% evidence | 10.8/20 RS sector -7.3% · RS bench 9.2% · 1Y 1.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 6 + 8.6 + 10.8 = 49.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17DigitalOcean Holdings, Inc.DOCN | 49.8/100Thin evidence · provisional56% evidence | ASLEEP | 17.3/35 Revenue 17.7% · PAT 100% · OPM change -3.7 pp 53% evidence | 11.2/25 ROCE 2.2% · OPM 14.2% 57% evidence | 10.1/20 P/E 37.5× · PEG — 15% evidence | 11.2/20 RS sector 13.7% · RS bench 33.5% · 1Y 238.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 11.2 + 10.1 + 11.2 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Check Point Software Technologies Ltd.CHKP | 45.1/100Thin evidence · provisional56% evidence | TURNING | 14.8/35 Revenue — · PAT — · OPM change -3 pp 39% evidence | 14.2/25 ROCE 3.8% · OPM 27.7% 76% evidence | 11.2/20 P/E 13.5× · PEG — 15% evidence | 4.9/20 RS sector -31.8% · RS bench -18.9% · 1Y -30.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 14.2 + 11.2 + 4.9 = 45.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Cloudflare, Inc.NET | 43.5/100Mixed-negative evidence61% evidence | LEADER | 12.7/35 Revenue 33.6% · PAT — · OPM change -16.5 pp 62% evidence | 4.0/25 ROCE -4.8% · OPM -29.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.8/20 RS sector 16.1% · RS bench 36.3% · 1Y 43.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 4 + 10 + 16.8 = 43.5 · Decision use: Price leads the evidence: RS versus the benchmark is 36.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20MongoDB, Inc.MDB | 42.6/100Mixed-negative evidence61% evidence | LEADER | 20.9/35 Revenue 23.7% · PAT — · OPM change 6.2 pp 62% evidence | 5.4/25 ROCE -0.8% · OPM -3.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.3/20 RS sector -12.6% · RS bench 3.2% · 1Y 16.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 5.4 + 10 + 6.3 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Palo Alto Networks, Inc.PANW | 42.1/100Mixed-negative evidence75% evidence | LEADER | 8.5/35 Revenue 24.5% · PAT -72.9% · OPM change -8.5 pp 95% evidence | 9.3/25 ROCE 2.1% · OPM 5% 76% evidence | 9.1/20 P/E 96.2× · PEG — 15% evidence | 15.2/20 RS sector 30.6% · RS bench 52% · 1Y 80.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 8.5 + 9.3 + 9.1 + 15.2 = 42.1 · Decision use: Price leads the evidence: RS versus the benchmark is 52%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22Akamai Technologies, Inc.AKAM | 40.8/100Mixed-negative evidence66% evidence | ASLEEP | 12.7/35 Revenue 6.1% · PAT -4% · OPM change -4.5 pp 53% evidence | 11.5/25 ROCE 1.2% · OPM 10.7% 57% evidence | 14.0/20 P/E 38.7× · PEG 0.7 65% evidence | 2.6/20 RS sector -20.4% · RS bench -5.6% · 1Y 37%4 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 11.5 + 14 + 2.6 = 40.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 23Zscaler, Inc.ZS | 39.8/100Mixed-negative evidence61% evidence | TURNING | 17.5/35 Revenue 24.6% · PAT — · OPM change 0.2 pp 62% evidence | 5.0/25 ROCE -0.9% · OPM -3.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.3/20 RS sector -22.1% · RS bench -8.2% · 1Y -34.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 5 + 10 + 7.3 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24VeriSign, Inc.VRSN | 37.0/100Mixed-negative evidence81% evidence | TURNING | 10.5/35 Revenue 6.9% · PAT 6.5% · OPM change -0.3 pp 83% evidence | 10.2/25 ROCE -1203.5% · OPM 68.2% 76% evidence | 7.6/20 P/E 27× · PEG 2.65 65% evidence | 8.7/20 RS sector -9.9% · RS bench 6.5% · 1Y 5.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10.5 + 10.2 + 7.6 + 8.7 = 37 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25CoreWeave, Inc.CRWV | 33.6/100Adverse evidence61% evidence | ASLEEP | 16.4/35 Revenue 100% · PAT — · OPM change -3.5 pp 62% evidence | 5.8/25 ROCE -0.1% · OPM -1.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.4/20 RS sector -31.1% · RS bench -18.4% · 1Y -33.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 5.8 + 10 + 1.4 = 33.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Block, Inc.XYZ | 32.0/100Adverse evidence71% evidence | FADING | 9.0/35 Revenue 5.1% · PAT -87.9% · OPM change -1.2 pp 83% evidence | 8.8/25 ROCE 1.6% · OPM 6.8% 76% evidence | 8.8/20 P/E 135.7× · PEG — 15% evidence | 5.4/20 RS sector -12.7% · RS bench 2.9% · 1Y -0.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 9 + 8.8 + 8.8 + 5.4 = 32 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Synopsys, Inc.SNPS | 31.4/100Adverse evidence81% evidence | BASING | 12.2/35 Revenue 39.5% · PAT -41.8% · OPM change -18.2 pp 83% evidence | 9.7/25 ROCE 0.4% · OPM 5.3% 76% evidence | 8.5/20 P/E 111.7× · PEG 1.78 65% evidence | 1.0/20 RS sector -32.8% · RS bench -20.1% · 1Y -23.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.2 + 9.7 + 8.5 + 1 = 31.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Cerebras Systems Inc.CBRS | 43.7/100Thin evidence · provisional41% evidence | ASLEEP | 20.1/35 Revenue 90.5% · PAT — · OPM change -209.7 pp 62% evidence | 3.6/25 ROCE -9.5% · OPM -265% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 6 weeks ahead 0% evidence |
| Exact sum: 20.1 + 3.6 + 10 + 10 = 43.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Oracle Corporation's stock price today?
Oracle Corporation trades at $143, −53.6% over the past year. The company is valued at $433 B. The stock sits at 16% of its 52-week range of $115–$293, −14.2% versus its 200-day average. On the tape, the price is in a downtrend, 15 weeks in. — as of 17 September 2026.
What were Oracle Corporation's latest quarterly results?
Oracle Corporation reported revenue of $19.3 B and net profit of $4.7 B for the Aug 26 quarter. Revenue rose 29.5% and profit rose 59.7% year on year. Earnings per share were $1.56. The operating margin was 35.3%, 4.0 pp higher than a year earlier. — as of 17 September 2026.
What is Oracle Corporation's revenue?
Oracle Corporation reported revenue of $19.3 B in the Aug 26 quarter, +29.5% year on year. For the full FY26 fiscal year, revenue was $67.4 B (+17.4%). Over the last 4 years revenue compounded at 12.2% a year. — as of 17 September 2026.
What is Oracle Corporation's profit?
Oracle Corporation earned $4.7 B of net profit in the Aug 26 quarter, +59.7% year on year — the 4th straight quarter of growth. Full-year FY26 profit was $17.0 B. The operating margin ran 35.3% in the latest quarter. — as of 17 September 2026.
What is Oracle Corporation's market cap?
Oracle Corporation's market capitalisation is $433 B at a stock price of $143. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Oracle Corporation's P/E ratio?
Oracle Corporation trades at a P/E of 22.0×, at the 1st percentile of its own 4-year range, against a long-run median of 33.9×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Oracle Corporation pay a dividend?
Yes — Oracle Corporation declared $0.50 per share for Aug 26, and $2.00 per share across the last four reported quarters. — as of 17 September 2026.
What is Oracle Corporation's dividend per share?
Oracle Corporation's most recently declared dividend is $0.50 per share for Aug 26, giving $2.00 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is Oracle Corporation's dividend yield?
Oracle Corporation's trailing dividend yield is 1.40%: $2.00 declared per share across the last four reported quarters, against a share price of $143. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
Is Oracle Corporation overvalued?
On its own history, Oracle Corporation looks cheap: its P/E of 22.0× has been cheaper only 1% of the time in 4 years (long-run median 33.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is Oracle Corporation growing?
Yes — Oracle Corporation is growing: latest-quarter revenue +29.5% year on year, profit +59.7%, and the margin +4.0 pp at 35.3%. The 4-year compound rates are 12.2% (revenue) and 26.1% (profit). The earnings engine currently reads: improving — as of 17 September 2026.
How is Oracle Corporation performing?
Oracle Corporation is in a downtrend, 15 weeks in. Its latest quarter's revenue rose 29.5% and profit rose 59.7% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 13 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is Oracle Corporation in?
Mixed — the growth curves are steadily positive, but ROCE at 12.4% is below the 15% bar this page requires to call it Consistent. The read comes from the last 12 quarters of growth (revenue growth +21.6% latest, profit growth +50.4% latest, eps growth +47.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is Oracle Corporation in an uptrend?
No — the price is in a downtrend (week 15 of stage 4), trading −14.2% versus its 200-day average and at 16% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Oracle Corporation beating the market?
Not lately — on a trailing-13-week view Oracle Corporation is currently behind the S&P 500 (13 weeks and counting; last ahead the week of 2026-06-18), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +250% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.
Will Oracle Corporation's stock price go up?
This page publishes no price forecast for Oracle Corporation. What it measures instead: the stock price is $143, the price is in a downtrend 15 weeks in. Its P/E of 22.0× sits at the 1st percentile of its own 4-year range. Direction is not something this site claims to know. — as of 17 September 2026.
Is the market betting against Oracle Corporation?
Somewhat — short interest is 2.4% of Oracle Corporation's tradable float, about 1.8 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Oracle Corporation have too much debt?
It carries real leverage — Oracle Corporation's debt-to-equity is 2.52. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Oracle Corporation's capex?
Oracle Corporation spent $84.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was $55.7 B. — as of 17 September 2026.
What is Oracle Corporation's cash flow?
Oracle Corporation generated $32.0 B of operating cash flow in FY26 and $−23.7 B of free cash flow after $55.7 B of capital spending. Reported profit that year was $17.0 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is Oracle Corporation's profit real cash?
Yes — over the last 3 fiscal years, 179% of Oracle Corporation's reported profit arrived as operating cash. In FY26, operating cash was $32.0 B against reported profit of $17.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Oracle Corporation?
On the balance sheet, the Z-score reads 1.93 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 17 September 2026.
Where is Oracle Corporation in its business cycle?
Oracle Corporation's FY26 operating margin was 33.2%, against a 5-year band of 27.4%–37.3%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 35.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Oracle Corporation story?
The sharpest disagreement: annual EPS moved +34.3% against a −53.6% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Oracle Corporation a stock worth studying right now?
This is not investment advice. The machine read: Oracle Corporation's earnings have outrun its stock. EPS grew +34.3% in a year against a −53.6% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!